Effects of Atorvastatin on the Intracellular Stability and Secretion of Apolipoprotein B in HepG2 Cells

From the Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada (A.M., J.M., T.R., D.D., K.A.); and Parke-Davis Pharmaceutical Research, Warner-Lambert Co, Ann Arbor, Mich (R.N.).

Correspondence to Khosrow Adeli, Department of Chemistry and Biochemistry, University of Windsor, 401 Sunset Ave, Windsor, Ontario, Canada N9B 3P4. E-mail adeli{at}uwindsor.ca

Abstract—We investigated the effects of atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the biogenesis of apolipoprotein B (apoB) in intact and permeabilized HepG2 cells. Intact cells were pretreated either with single or multiple doses of atorvastatin (0.1 to 20 µmol/L) for periods of 6 to 20 hours and pulsed with [³⁵S]methionine. In some cases the cells were permeabilized with digitonin. Experiments were performed to investigate the effects of atorvastatin on (1) the rates of lipid synthesis and secretion, (2) the synthesis and accumulation of apoB, (3) the intracellular stability of apoB, (4) the amount of apoB-containing lipoprotein particles assembled in HepG2 microsomes, and (5) the secretion and accumulation of apoB into the culture medium. ApoB synthesis, degradation, and secretion were measured by pulse-chase experiments with [³⁵S]methionine in both intact and permeabilized HepG2 cells. Lipid synthesis was assessed by pulse-labeling experiments with [³H]acetate or [³H]oleate bound to bovine serum albumin. Comparisons were made under basal conditions and in the presence of oleate (0.36 µmol/L). Atorvastatin acutely inhibited the synthesis of cholesterol and cholesterol ester but did not have a significant effect on triglyceride or phospholipid synthesis. Atorvastatin did not affect the uptake of [³⁵S]methionine by the cells nor did it influence the synthesis of apoB or a control protein, albumin. However, atorvastatin reduced the secretion of apoB into the culture medium, apparently by enhancing the degradation of apoB in the cell under basal and induced conditions with oleate. The stability of apoB associated with the lipoprotein particles was also significantly lowered by atorvastatin. The stimulated degradation of apoB in atorvastatin-treated cells was sensitive to MG132, a proteasome inhibitor. The net effect of atorvastatin was a reduction in the number of apoB-containing lipoprotein particles of different sizes isolated from microsomes and a reduction in apoB secretion into the culture medium. The data suggest that atorvastatin may impair the translocation of apoB into the lumen of the endoplasmic reticulum, thus increasing the amount of apoB degraded intracellularly. It is hypothesized that atorvastatin alters these parameters primarily as a result of inhibiting cholesterol synthesis and limiting the availability of cholesterol and/or cholesterol ester for the normal assembly of apoB-containing lipoprotein particles.

Key Words: apolipoprotein B • atorvastatin • HMG-CoA reductase inhibitor • degradation • translocation • secretion

This article has been cited by other articles:

				M. Castro Cabezas, C. Verseyden, S. Meijssen, H. Jansen, and D. W. Erkelens Effects of Atorvastatin on the Clearance of Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5972 - 5980. [Abstract] [Full Text] [PDF]

				C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF]

				K. Ouguerram, T. Magot, Y. Zair, J. S. Marchini, B. Charbonnel, H. Laouenan, and M. Krempf Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 332 - 337. [Abstract] [Full Text] [PDF]

				S. Pal, N. Ho, C. Santos, P. Dubois, J. Mamo, K. Croft, and E. Allister Red Wine Polyphenolics Increase LDL Receptor Expression and Activity and Suppress the Secretion of ApoB100 from Human HepG2 Cells J. Nutr., March 1, 2003; 133(3): 700 - 706. [Abstract] [Full Text] [PDF]

				C. Patterson and D. Cyr Welcome to the Machine: A Cardiologist's Introduction to Protein Folding and Degradation Circulation, November 19, 2002; 106(21): 2741 - 2746. [Full Text] [PDF]

				M. Guerin, P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4991 - 5000. [Abstract] [Full Text] [PDF]

				N. Roglans, E. Sanguino, C. Peris, M. Alegret, M. Vazquez, T. Adzet, C. Diaz, G. Hernandez, J. C. Laguna, and R. M. Sanchez Atorvastatin Treatment Induced Peroxisome Proliferator-Activated Receptor alpha Expression and Decreased Plasma Nonesterified Fatty Acids and Liver Triglyceride in Fructose-Fed Rats J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 232 - 239. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. R. Barrett, T. A. Mori, L. J. Beilin, and T. G. Redgrave Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2283 - 2289. [Abstract] [Full Text] [PDF]

				M. Guerin, T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman Action of Atorvastatin in Combined Hyperlipidemia : Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 189 - 197. [Abstract] [Full Text] [PDF]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs Endocrinology, November 1, 1999; 140(11): 5293 - 5302. [Abstract] [Full Text]

				L. J. Wilcox, P. H. R. Barrett, and M. W. Huff Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin J. Lipid Res., June 1, 1999; 40(6): 1078 - 1089. [Abstract] [Full Text]

				L. J. Wilcox, P. H. R. Barrett, R. S. Newton, and M. W. Huff ApoB100 Secretion From HepG2 Cells is Decreased by the ACAT Inhibitor CI-1011 : An Effect Associated With Enhanced Intracellular Degradation of ApoB Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 939 - 949. [Abstract] [Full Text] [PDF]

				A. Theriault, Q. Wang, A. Gapor, and K. Adeli Effects of {gamma}-Tocotrienol on ApoB Synthesis, Degradation, and Secretion in HepG2 Cells Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 704 - 712. [Abstract] [Full Text] [PDF]

				Z. Zhang, K. Cianflone, and A. D. Sniderman Role of Cholesterol Ester Mass in Regulation of Secretion of ApoB100 Lipoprotein Particles by Hamster Hepatocytes and Effects of Statins on That Relationship Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 743 - 752. [Abstract] [Full Text] [PDF]